Metformin and Oral Contraceptives in PCOS
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00451568|
Recruitment Status : Completed
First Posted : March 23, 2007
Last Update Posted : April 13, 2015
Background: PCOS is a common condition with a prevalence of 5-8 % in premenopausal women. More than 50% of PCOS patients are insulin resistant and have a diabetes risk 5-8 times higher than age- and weight-matched controls. Studies using insulin sensitizers in PCOS found increased insulin sensitivity and decreased insulin levels to be followed by decreased androgen levels and improved ovulatory function. No studies however, evaluated the long term effects of insulin sensitizing treatment.
Oral contraceptives normalize menstrual cycles and suppress androgen levels in PCOS, however no long-term studies evaluated the effects of combined treatment with metformin and oral contraceptives in PCOS.
Design: Randomized open study in 3*30 PCOS patients. Patients are randomised to 24 months of treatment with 1: metformin, 2: metformin and oral contraceptives or 3: oral contraceptives.
Primary outcome measures: fasting insulin, AUC insulin. Secundary endpoints: BMI, WHR, LH, FSH, total and free-testosterone, c-peptid, urinary cortisol, AUC for insulin, glucose and c-peptid during OGTT.
- Irregular menses or anovulaty cycles
- High free testosterone > 0,035 nmol/l or hirsutism
- PCO in vaginal US Criteria 1 and 2 OR 2 and 3.
|Condition or disease||Intervention/treatment||Phase|
|Polycystic Ovary Syndrome||Drug: Metformin Drug: Desorelle||Phase 4|
90 patients are included and randomized to 12 months of treatment with metformin (1000+1000 mg/d) or OCP (150 mg desogestrel 30 microgram ethinylestradiol) or combined treatment (metformin+OCP).
Patients attend a biochemical and physical examination at study inclusion and at 12 months. Patients attend for registration of side effects and compliance after 6 months of study duration. Safety tests are performed at all three visits and include weight, blood pressure, HbA1c, liver enzymes, electrolytes, and white blood cell count. Pregnancy tests are performed by the participants each month. Patients are given general advice on lifestyle intervention. Patients are excluded if they initiated medical treatment with possible hormonal and metabolic effects during the intervention period. Lifestyle intervention is allowed. Laser treatment is offered to patients with moderate or severe facial hirsutism and patients are allowed to shave/wax. The patients accept not applying cosmetic treatment 3-4 days before attending for evaluation at the clinic.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||90 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Metformin and Oral Contraceptives in PCOS|
|Study Start Date :||March 2007|
|Primary Completion Date :||January 2012|
|Study Completion Date :||April 2013|
Active Comparator: 1
500 mg 2 tablets 2 times a day
Active Comparator: 2
1 tablet/day in 21 days
Active Comparator: 3
desorelle + metformin
500 mg 2 tablets 2 times a dayDrug: Desorelle
1 tablet/day in 21 days
- Changes in fasting insulin and area under the curve for insulin (2 hours) [ Time Frame: 12 months ]
- Changes in BMD, BMI, WHR, LH, FSH, total and free testosterone, fasting blood glucose, fasting C-peptide, urine-cortisol secretion, body composition, number of hypoglycaemic cases, AUC for insulin, glucose and C-peptide during OGTT (2 and 5 ho [ Time Frame: 12 months ]
- Changes in cortisol metabolism [ Time Frame: 12 months ]
- Changes in the prevalence of reactive hypoglycemia and areal under the curve for glucose (5 hours) [ Time Frame: 12 months ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00451568
|Odense University Hospital|
|Principal Investigator:||Marianne Andersen, MD, PhD||Odense University Hospital|